Search research articles
Contact Us
Filters
Showing results (351-360 of 391) with videos related to
Page
of 40
Sort By:
Gynecologic Oncology
|
October 23, 2022
Clinical and molecular characteristics of ARIEL3 patients who derived exceptional benefit from rucaparib maintenance treatment for high-grade ovarian carcinoma
David M O'Malley, Amit M Oza, Domenica Lorusso, et al.
Molecular Cancer Therapeutics
|
October 13, 2017
PPARγ Ligand-induced Annexin A1 Expression Determines Chemotherapy Response via Deubiquitination of Death Domain Kinase RIP in Triple-negative Breast Cancers
Luxi Chen, Yi Yuan, Shreya Kar, et al.
European Urology Oncology
|
February 22, 2026
WOMBAT (ANZUP 2201): A Phase 2, Single-arm Study of Bipolar Androgen Therapy in Patients with Nonmetastatic Castration-resistant Prostate Cancer with Prostate-specific Antigen Progression on Darolutamide
Barak Talmor, Carole A Harris, Christopher Gianacas, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 29, 2019
Phase Ib study of atezolizumab combined with cobimetinib in patients with solid tumors
M D Hellmann, T-W Kim, C B Lee, et al.
Nature Communications
|
September 28, 2018
Mitochondrial uncoupling reveals a novel therapeutic opportunity for p53-defective cancers
R Kumar, L Coronel, B Somalanka, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
June 9, 2021
Rucaparib maintenance treatment for recurrent ovarian carcinoma: the effects of progression-free interval and prior therapies on efficacy and safety in the randomized phase III trial ARIEL3
Andrew R Clamp, Domenica Lorusso, Amit M Oza, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 9, 2026
Urinary Biomarkers Objectively Measure Minimal Residual Disease in Non-Muscle-Invasive Bladder Cancer
Andrew B Katims, Charlie White, Syed Muneeb Alam, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 20, 2024
Adjuvant Nivolumab for Localized Renal Cell Carcinoma at High Risk of Recurrence After Nephrectomy: Part B of the Randomized, Placebo-Controlled, Phase III CheckMate 914 Trial
Robert J Motzer, Axel Bex, Paul Russo, et al.
The Lancet. Oncology
|
May 4, 2020
Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): post-progression outcomes and updated safety results from a randomised, placebo-controlled, phase 3 trial
Jonathan A Ledermann, Amit M Oza, Domenica Lorusso, et al.
Cancer Medicine
|
September 22, 2021
Maintenance treatment with rucaparib for recurrent ovarian carcinoma in ARIEL3, a randomized phase 3 trial: The effects of best response to last platinum-based regimen and disease at baseline on efficacy and safety
Ana Oaknin, Amit M Oza, Domenica Lorusso, et al.
Page
of 40
Search research articles
Search
Showing results (351-360 of 391) with videos related to
Sort By:
Page
of 40
Gynecologic Oncology
|
October 23, 2022
Clinical and molecular characteristics of ARIEL3 patients who derived exceptional benefit from rucaparib maintenance treatment for high-grade ovarian carcinoma
David M O'Malley, Amit M Oza, Domenica Lorusso, et al.
Molecular Cancer Therapeutics
|
October 13, 2017
PPARγ Ligand-induced Annexin A1 Expression Determines Chemotherapy Response via Deubiquitination of Death Domain Kinase RIP in Triple-negative Breast Cancers
Luxi Chen, Yi Yuan, Shreya Kar, et al.
European Urology Oncology
|
February 22, 2026
WOMBAT (ANZUP 2201): A Phase 2, Single-arm Study of Bipolar Androgen Therapy in Patients with Nonmetastatic Castration-resistant Prostate Cancer with Prostate-specific Antigen Progression on Darolutamide
Barak Talmor, Carole A Harris, Christopher Gianacas, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 29, 2019
Phase Ib study of atezolizumab combined with cobimetinib in patients with solid tumors
M D Hellmann, T-W Kim, C B Lee, et al.
Nature Communications
|
September 28, 2018
Mitochondrial uncoupling reveals a novel therapeutic opportunity for p53-defective cancers
R Kumar, L Coronel, B Somalanka, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
June 9, 2021
Rucaparib maintenance treatment for recurrent ovarian carcinoma: the effects of progression-free interval and prior therapies on efficacy and safety in the randomized phase III trial ARIEL3
Andrew R Clamp, Domenica Lorusso, Amit M Oza, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 9, 2026
Urinary Biomarkers Objectively Measure Minimal Residual Disease in Non-Muscle-Invasive Bladder Cancer
Andrew B Katims, Charlie White, Syed Muneeb Alam, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 20, 2024
Adjuvant Nivolumab for Localized Renal Cell Carcinoma at High Risk of Recurrence After Nephrectomy: Part B of the Randomized, Placebo-Controlled, Phase III CheckMate 914 Trial
Robert J Motzer, Axel Bex, Paul Russo, et al.
The Lancet. Oncology
|
May 4, 2020
Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): post-progression outcomes and updated safety results from a randomised, placebo-controlled, phase 3 trial
Jonathan A Ledermann, Amit M Oza, Domenica Lorusso, et al.
Cancer Medicine
|
September 22, 2021
Maintenance treatment with rucaparib for recurrent ovarian carcinoma in ARIEL3, a randomized phase 3 trial: The effects of best response to last platinum-based regimen and disease at baseline on efficacy and safety
Ana Oaknin, Amit M Oza, Domenica Lorusso, et al.
Page
of 40